Hetero entered into the development of Biosimilar products in 2009. Our capabilities in R&D have once again come to the fore with the launch of several biosimilar products – Darbepoetin alfa, Rituximab, Bevacizumab and Adalimumab in India within 5 years of initiation.

When it comes to Biosimilars, we have the advantage of single site state-of-the-art manufacturing and R & D and adherence to global standards. With few more pipeline products close to actualization we are confident of introducing more biosimilar products in the future.

For detailed information on our biologics business, please visit: www.heterobiopharma.com

Hetero has the distinction of bringing 4 biosimilar products to market within 5 years of inception. This has placed us amongst the select biotech companies with the capability to develop, manufacture and commercialize complex monoclonal antibodies (mAbs).